A. Maniakas et al. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000–2019. JAMA Oncol. 6, 1397–1404 (2020)

Article  PubMed  Google Scholar 

A. Maniakas, M. Zafereo, M.E. Cabanillas, Anaplastic Thyroid Cancer: New Horizons and Challenges. Endocrinol. Metab. Clin. North Am. 51, 391–401 (2022)

Article  PubMed  Google Scholar 

I. Califano, A. Smulever, F. Jerkovich, F. Pitoia, Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease. Rev. Endocr. Metab. Disord. (2023) https://doi.org/10.1007/s11154-023-09833-1

L. Lorusso et al. Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. Int. J. Mol. Sci. 22, 3117 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. De Leo, M. Trevisan, L. Fugazzola, Recent advances in the management of anaplastic thyroid cancer. Thyroid Res. 13, 17 (2020)

Article  PubMed  PubMed Central  Google Scholar 

A. Matrone et al. Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses. Front. Oncol. 12, 854755 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

V. Vander Poorten et al. Effectiveness of core needle biopsy in the diagnosis of thyroid lymphoma and anaplastic thyroid carcinoma: A systematic review and meta-analysis. Front. Endocrinol. 13, 971249 (2022)

Article  Google Scholar 

S.N. Rao, R.C. Smallridge, Anaplastic thyroid cancer: An update. Best Pract. Res. Clin. Endocrinol. Metab. 37, 101678 (2023)

Article  CAS  PubMed  Google Scholar 

R.A. Ghossein, N. Katabi, J.A. Fagin, Immunohistochemical Detection of Mutated BRAF V600E Supports the Clonal Origin of BRAF-Induced Thyroid Cancers Along the Spectrum of Disease Progression. J. Clin. Endocrinol. Metab. 98, E1414–E1421 (2013)

Article  CAS  PubMed  PubMed Central  Google Scholar 

C.-F. Chang et al. The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan. Am. J. Cancer Res. 12, 5342–5350 (2022)

CAS  PubMed  PubMed Central  Google Scholar 

S.N. Rao et al. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid 27, 672–681 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Al-Jundi, S. Thakur, S. Gubbi, J. Klubo-Gwiezdzinska, Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review. Cancers 12, 2104 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

C. Romei et al. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience. Oncol. Lett. 15, 9174–9182 (2018)

PubMed  PubMed Central  Google Scholar 

L. Cheng, K. Newbold, Genomic landscape of anaplastic thyroid cancer and implications on therapy. Curr. Opin. Endocrine Metabol. Res. 30, 100458 (2023)

Article  CAS  Google Scholar 

L. Schubert, M.L. Mariko, J. Clerc, O. Huillard, L. Groussin, MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data. Cancers 15, 710 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

R.S. Scheffel, J.M. Dora, A.L. Maia, BRAF mutations in thyroid cancer. Curr. Opin. Oncol. 34, 9 (2022)

Article  CAS  PubMed  Google Scholar 

V. Subbiah et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clinic Oncology 36, 7 (2018).

Article  CAS  Google Scholar 

M.E. Cabanillas et al. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid 28, 945–951 (2018)

Article  PubMed  PubMed Central  Google Scholar 

K.C. Bible et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 31, 337–386 (2021)

Article  PubMed  PubMed Central  Google Scholar 

A. Silver Karcioglu, A.J. Iwata, M. Pusztaszeri, A.H. Abdelhamid Ahmed, G.W. Randolph, The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines. Cancer Cytopathol. 130, 174–180 (2022)

Article  PubMed  Google Scholar 

J.R. Wang et al. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 29, 1036–1043 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

E. Maurer et al. Mutation-based, short-term “neoadjuvant” treatment allows resectability in stage IVB and C anaplastic thyroid cancer. Eur. Arch. Otorhinolaryngol. 280, 1509–1518 (2023)

Article  PubMed  PubMed Central  Google Scholar 

M. Ouzzani, H. Hammady, Z. Fedorowicz, A. Elmagarmid, Rayyan—a web and mobile app for systematic reviews. Syst. Rev. 5, 2010 (2016)

N. Liu, Y. Zhou, J.J. Lee, IPDfromKM: Reconstruct Individual Patient Data from Published Kaplan-Meier Survival Curves. (2020) https://www.trialdesign.org/one-page-shell.html#IPDfromKM

J.A. Sterne et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ i4919 (2016) https://doi.org/10.1136/bmj.i4919

G. Wells et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses (2000) https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

M.J. Page et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021)

Article  PubMed  PubMed Central  Google Scholar 

S. McGrath, H. Sohn, R. Steele, A. Benedetti, Meta‐analysis of the difference of medians. Biometrical J. 62, 69–98 (2020)

Article  Google Scholar 

F. Bueno et al. Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience. Endocrine 80, 134–141 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

F. Platini et al. BRAF V600E-mutated anaplastic thyroid carcinoma (ATC) and treatment with BRAF-inhibitors: Real-world data from a single-institution, still far from the cure. JCO 38, e18577 (2020)

Article  Google Scholar 

C. Lorimer et al. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer – Real-World Outcomes From UK Centres. Clin. Oncol. 35, e60–e66 (2023)

Article  CAS  Google Scholar 

T.N. Da Silva et al. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study. Eur. J. Endocrinol. 188, 31–38 (2023)

Article  Google Scholar 

V. Subbiah et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat. Med. 29, 1103–1112 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

X. Zhao et al. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF V600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid 33, 484–491 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Cabanillas et al. BRAF/MEK Inhibitor Plus Immunotherapy for BRAF V600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 32, A-136–A-174 (2022)

Google Scholar 

D.M. Hyman et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N. Engl J. Med. 373, 726–736 (2015)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Leboulleux et al. A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer. Clin. Cancer Res. 29, 2401–2409 (2023)

Article  CAS